Guide / Multi-site cohorts

Designing multi-site medical imaging cohorts

A multi-site medical imaging cohort should define why each source is included, how site and scanner variation will be measured, how patients are separated across development and validation, and whether clinical labels remain comparable. MedCorpora assesses these controls against verified participating-source inventory and programme authority.

Published 30 July 2026 · Reviewed 12 August 2026 · MedCorpora
SourcesHospitals · scanners · protocols
DesignDevelopment · holdout · external
EvidenceComparable ground truth
RiskSite leakage and hidden confounding
01

What the programme covers

Adding hospitals can improve diversity, but it can also create shortcuts when disease prevalence, acquisition protocol or label source is strongly tied to site. A defensible design measures these distributions and assigns sources according to the intended claim.

02

What a useful specification includes

A defensible request defines the clinical task, source evidence and acceptance criteria before patient-level data moves. The exact fields and thresholds depend on the intended model claim.

  • Role of each source site in the study design
  • Patient, site, scanner and time separation
  • Protocol and device-distribution targets
  • Comparable inclusion and ground-truth rules
  • Population, prevalence and subgroup requirements
  • Per-site minimums and uncertainty thresholds
03

Quality and validation controls

Multi-site quality review separates true clinical variation from source-specific formatting, workflow or label artifacts. Site identifiers remain available for governed analysis when necessary and permitted.

  • Cross-site patient and duplicate controls
  • Scanner and protocol distributions
  • Site-specific missingness and label sources
  • Prevalence and population differences
  • Holdout integrity and site-shortcut analysis
04

Availability, rights and delivery

A multi-site release proceeds only for sources with verified inventory and programme-specific authorization. Additional countries or sites in a sourcing scope remain under feasibility until those conditions are met.

Public pages describe a sourcing and engineering capability, not guaranteed ready inventory. Each release remains subject to verified programme inventory, programme-specific authorization, privacy review, technical acceptance and buyer licence terms.

05

Questions, answered directly.

Is more sites always better?

No. Source relevance, label comparability, permissions and study design matter more than an unqualified site count.

Can one hospital be held out for validation?

Yes when it provides an appropriate independent population and sufficient eligible cases.

How is patient overlap prevented?

Identity-safe resolution and patient-level split rules are applied where the programme can reliably detect overlap.

Can sites from different countries be combined?

Potentially, subject to buyer-specific feasibility, applicable permissions, privacy controls and compatible cohort definitions.

Institutional engagement

Define the cohort.